Dynamic alterations in chemokine gradients  induce transendothelial shuttling of human T  cells under physiologic shear conditions.
The active movement of cells from subendothelial compartments into the bloodstream (intravasation) has been recognized for several decades by histologic and physiologic studies, yet the molecular effectors of this process are relatively uncharacterized. For extravasation, studies based predominantly on static transwell assays support a general model, whereby transendothelial migration (TEM) occurs via chemoattraction toward increasing chemokine concentrations. However, this model of chemotaxis cannot readily reconcile how chemokines influence intravasation, as shear forces of blood flow would likely abrogate luminal chemokine gradient(s). Thus, to analyze how T cells integrate perivascular chemokine signals under physiologic flow, we developed a novel transwell-based flow chamber allowing for real-time modulation of chemokine levels above (luminal/apical compartment) and below (abluminal/subendothelial compartment) HUVEC monolayers. We routinely observed human T cell TEM across HUVEC monolayers with the combination of luminal CXCL12 and abluminal CCL5. With increasing concentrations of CXCL12 in the luminal compartment, transmigrated T cells did not undergo retrograde transendothelial migration (retro-TEM). However, when exposedto abluminal CXCL12, transmigrated T cells underwent striking retro-TEM and re-entered the flow stream [corrected]. This CXCL12 fugetactic (chemorepellant) effect was concentration-dependent, augmented by apical flow, blocked by antibodies to integrins, and reduced by AMD3100 in a dose-dependent manner. Moreover, CXCL12-induced retro-TEM was inhibited by PI3K antagonism and cAMP agonism. These findings broaden our understanding of chemokine biology and support a novel paradigm by which temporospatial modulations in subendothelial chemokine display drive cell migration from interstitial compartments into the bloodstream.
Lee
Jack Y
JY
Harvard Skin Disease Research Center and Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Buzney
Catherine D
CD
Poznansky
Mark C
MC
Sackstein
Robert
R
D019380:Anti-HIV Agents / Q000276:immunology / Q000494:pharmacology; D001596:Benzylamines; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000276:immunology* / Q000494:pharmacology; D054377:Chemokine CXCL12 / Q000276:immunology* / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects / Q000276:immunology*; D018920:Coculture Techniques; D000080027:Cyclams; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology*; D006571:Heterocyclic Compounds / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D013312:Stress, Physiological / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
D019380:Anti-HIV Agents; D001596:Benzylamines; C483024:CCL5 protein, human; C515255:CXCL12 protein, human; D018946:Chemokine CCL5; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor